South Korea’s financial regulator has ordered a halt to the sale of whole-life insurance products engineered to return 100% of premiums at the seven-year mark, removing a product category from the market rather than penalising individual sellers.
The Financial Supervisory Service (FSS) issued supervisory guidance on September 21 directing life insurers to suspend sales of so-called “700 whole-life” policies by end of September, according to Seoul Economic Daily. These products return less than total premiums paid on early cancellation, then sharply raise the surrender value at the seven-year mark to refund the full amount. The FSS concluded the design leads consumers to treat the policies as savings products rather than insurance.
The ban has roots in a market shift from more than a decade ago. A 2015 deregulation allowed South Korean insurers to design their own products without following prior standardized templates. Since then, 99% of new life products have been self-developed offerings, according to the FSS – a volume that gave insurers significant design freedom while making it harder for the regulator to enforce disclosure standards consistently.
The 700 whole-life product is not the only category the FSS has identified. The September guidance named short-payment whole-life insurance, executive term insurance, and corporate-targeted policies as related examples – all marketed primarily on savings or surrender value features rather than protection.
This is not the first intervention of this kind. The Korea Times reported in November 2024 that the FSS had already criticised excessive competition in short-term payment life insurance and moved to restrict its sale, alongside actions against other product categories. Industry officials pushed back at the time.
“Due to frequent interventions by financial authorities in product sales, insurers have lost their motivation to develop new products. Many hope for a more considerate approach that encourages self-regulation and improvement within the industry, rather than constant external interference,” one company official told The Korea Times.
Another official said: “It seems that the more the FSS intervenes in sales-related matters, the harder it becomes to aggressively promote products.”
The September action on 700 whole-life products suggests the FSS has not changed course.
Read next: South Korean insurer consolidation narrows the field for brokers
The broader whole-life market has been contracting regardless of the latest regulatory action. FSS data cited by The Korea Times shows new whole-life contracts fell from 1.65 million in 2020 to 1.06 million in 2024. Over the same period, total contract value dropped approximately 45% – from 88.6 trillion won to 49.1 trillion won.
Consumer appetite has been a factor. One policyholder who cancelled a decade-long whole-life policy told The Korea Times the product “felt like an asset I couldn’t use and had forgotten about,” adding that cancellation – even at a loss of principal – was preferable to continuing premium payments.
Financial complaints across the sector have also risen. FSS figures show the number of cases increased from 93,842 in 2023 to 128,419 in 2025, a 36.9% jump, with insurance among the sectors recording the sharpest increases.
Samsung Life, Hanwha Life, and Kyobo Life – the three dominant carriers, which together hold close to half of the South Korean life market – are all understood to have established positions in short-payment whole-life products broadly, according to The Asia Business Daily.
South Korea’s action sits within a wider regional pattern. In September 2025, Hong Kong’s Insurance Authority (IA) and Hong Kong Monetary Authority (HKMA) issued a joint circular stating they had “observed that certain insurance products currently marketed in Hong Kong may create confusion among prospective policy holders regarding their nature” – specifically, that products with savings features “may be misunderstood as bank deposits.”
The circular requires all such products to include the word “insurance” in their names, in both English and Chinese. Phase one applied from January 1, 2026. Phase two – covering existing in-scope products still on sale – takes effect January 1, 2027.
Hong Kong moved on naming. South Korea moved on structure. Both regulators reached the same underlying conclusion: disclosure alone is insufficient when product design itself generates the confusion.
Read next: South Korea bills put GA commission bargaining power in focus
For brokers operating in South Korea, or managing clients holding whole-life portfolios, the FSS action leaves practical questions unanswered.
The first concerns in-force policies. The guidance covers new sales only and does not publicly address the position of policyholders already holding 700 whole-life contracts who are approaching the seven-year threshold. Brokers with clients in that window need carrier-level clarity on whether existing surrender value terms are affected.
The second is adjacent product risk. Short-payment whole-life, executive term, and corporate-targeted policies were named in the same FSS guidance. Brokers distributing any of these in South Korea should review their current book against the possibility of further regulatory action.
The third is the broader read across Asia. If regulators in both South Korea and Hong Kong are moving beyond disclosure to act on product structure and naming, brokers with cross-border portfolios should be identifying which products elsewhere carry the same savings-insurance ambiguity – and whether other regulators in the region are drawing the same conclusions.
